scholarly journals CD44 + cells determine fenofibrate‐induced microevolution of drug‐resistance in prostate cancer cell populations

Stem Cells ◽  
2020 ◽  
Vol 38 (12) ◽  
pp. 1544-1556 ◽  
Author(s):  
Tomasz Wróbel ◽  
Marcin Luty ◽  
Jessica Catapano ◽  
Elżbieta Karnas ◽  
Małgorzata Szczygieł ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cell Populations

scholarly journals CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

Oncotarget ◽  
2015 ◽  
Vol 6 (23) ◽  
pp. 19661-19670 ◽  
Author(s):  
Anchit Khanna ◽  
Jayant K. Rane ◽  
Kati K. Kivinummi ◽  
Alfonso Urbanucci ◽  
Merja A. Helenius ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cell ◽  
Therapeutic Target ◽  
Prostate Cancer Cell ◽  
Cell Populations

Role of the MDR-1-Encoded Multiple Drug Resistance Phenotype in Prostate Cancer Cell Lines

1993 ◽  
Vol 150 (5 Part 1) ◽  
pp. 1544-1547 ◽  
Author(s):  
Gerhard Theyer ◽  
Marion Schirmböck ◽  
Therese Thalhammer ◽  
Edward R. Sherwood ◽  
Gerhard Baumgartner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Cell Lines ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
Prostate Cancer Cell Lines ◽  
Mdr 1

Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15126-e15126
Author(s):  
Sharon A. Glynn ◽  
Aidan Toner ◽  
Joe Lewis ◽  
Frank Sullivan ◽  
Laura Breen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Mouse Models ◽  
Cell Lines ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Drug Resistant ◽  
Prostate Cancer Cell Lines ◽  
Androgen Independent

e15126 Background: EL102 is a dual-action drug promoting apoptosis and inhibiting angiogenesis. It exerts its action though the inhibition of Hif1a induced hypoxic signalling and induction of the Caspase 3/7 apoptotic cascade. The drug has equal activity in normoxia and hypoxia indicating it may be equally active in these different tumor compartments. We tested its ability to circumvent chemotherapeutic drug resistance. Methods: We assessed the ability of EL102 to inhibit prostate cancer cell proliferation and motility in vitro, calculating IC50s for CWR22, 22Rv2, PC3 and DU145 prostate cancer cell lines, comparing sensitivity between androgen dependent, androgen independent and metastatic prostate cancer. Additionally we assessed the activity of EL102 in combination with docetaxel in vitro and in murine CWR22 xenografts. The ability to overcome MDR1 and BCRP mediated drug resistance was also tested using DLKP drug resistant variants which exhibit 200 fold resistance to doxorubicin, docetaxel, paclitaxel and vincristine. Results: We found that prostate cancer cell lines are sensitive to EL102 with IC50s in the region of 10-50nM. Of particular interest was the identical sensitivity of the androgen independent 22Rv1 and its androgen dependent parent CWR22, suggesting ability to overcome hormone refractory prostate cancer. Additionally we demonstrate dose response for inhibition of cell motility in metastatic DU145. In CWR22 murine mouse models treatment with EL102 resulted in decreased tumor volume compared to control. A docetaxel and EL102 combination arm demonstrated the greater inhibition of tumor growth than EL102 or docetaxel alone. The lung cancer cell line DLKP, its drug resistant variants DLKPA (MDR1 overexpressing) and DLKPMitox (BCRP overexpressing) were equally sensitive to EL102 indicating that EL102 is not a substrate for MDR1 or BCRP. Conclusions: EL102 is a potential therapeutic for the treatment of prostate cancer, in particular in combination with docetaxel, and exhbibits the potential to overcome drug resistane. Future studies will include the efficacy of this drug in prostate cancer metastatic mouse models.

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

2009 ◽  
Vol 37 (3) ◽  
pp. 1269-1277 ◽  
Author(s):  
Ercument Cengiz ◽  
Burcak Karaca ◽  
Yuksel Kucukzeybek ◽  
Gurbuz Gorumlu ◽  
Mustafa K. Gul ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Cell Line ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Line ◽  
Prostate Cancer Cell Line

scholarly journals Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell

Molecules ◽  
2017 ◽  
Vol 22 (9) ◽  
pp. 1477 ◽  
Author(s):  
Chi-Ming Liu ◽  
Chiu-Li Kao ◽  
Yu-Ting Tseng ◽  
Yi-Ching Lo ◽  
Chung-Yi Chen
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Resistance Factors ◽  
Inhibit Cell Growth

664: CXCL12/CXCR4 Trans-Activation of HER2 in Lipid Rafts of Prostate Cancer Cell Membranes Promotes Bone Metastasis

2007 ◽  
Vol 177 (4S) ◽  
pp. 223-223
Author(s):  
Sreenivasa R. Chinni ◽  
Hamilto Yamamoto ◽  
Zhong Dong ◽  
Aaron Sabbota ◽  
Sanaa Nabha ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Lipid Rafts ◽  
Cancer Cell ◽  
Cell Membranes ◽  
Prostate Cancer Cell
Sign in / Sign up

Export Citation Format

Share Document